Applications of antisense and siRNAs during preclinical drug development

A significantly greater number of candidate drug targets and compounds are now being generated during preclinical drug development. To date, however, such increases have not led to improvements in clinical success rates or reduced times to market. There is a need for better strategies to prioritize targets and drug candidates. Antisense and siRNA technologies off er exceptional speed and specificity to address this need. In particular, antisense and siRNAs are beginning to be used in combination with expression profiling to evaluate drug specificity and mechanism-of-action, aiding in the identification of better candidates earlier in the drug development process.